Q-omics provides the consensus-scored TXNP4 profile across patient tissues and cancer cell-line models. TXNP4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TXNP4 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, TXNP4 RNA expression shows 10,488 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, LIHC, and LSCC as cancer lineages where TXNP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNP4 survival associations across molecular data types. TXNP4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNP4 RNA expression–survival associations across cancer types. High TXNP4 expression shows unfavorable associations in LUAD, BRCA, LIHC, SKCM and LGG, but favorable associations in READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TXNP4 RNA expression.
This table summarizes TXNP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TXNP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNP4 shows lower tumor expression in KIRC and higher tumor expression in LIHC, BRCA, LUSC, PAAD and CHOL. The LIHC box plot shows higher TXNP4 RNA expression in tumor versus normal tissue (log2 FC = +0.727, t-test p < 0.001).
This table shows molecular features associated with TXNP4 in patient tissues and cancer cell lines. In patient samples, TXNP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
